{"nctId":"NCT03439124","briefTitle":"Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia","startDateStruct":{"date":"2017-11-27","type":"ACTUAL"},"conditions":["Community-acquired Pneumonia (CAP)","Hospital-acquired Pneumonia (HAP)"],"count":138,"armGroups":[{"label":"Ceftobiprole medocaril","type":"EXPERIMENTAL","interventionNames":["Drug: ceftobiprole medocaril"]},{"label":"IV standard-of-care cephalosporin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: IV standard-of-care cephalosporin"]}],"interventions":[{"name":"ceftobiprole medocaril","otherNames":["ceftobiprole"]},{"name":"IV standard-of-care cephalosporin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male of female aged 3 months to \\< 18 years with a body weight of at least 5 kg\n* Diagnosis of either hospital-acquired pneumonia or community-acquired pneumonia requiring hospitalization and administration of IV antibiotic therapy\n* New or progressive imaging findings consistent with bacterial pneumonia\n* Requirement for IV antibacterial treatment for pneumonia\n* Other inclusion criteria may apply\n\nExclusion Criteria:\n\n* Known resistance of the causative pathogen to ceftobiprole or IV standard-of-care cephalosporin treatment (± vancomycin)\n* On mechanical ventilation\n* Chest trauma with severe lung contusion or flail chest\n* Acute respiratory distress syndrome\n* Empyema or lung abscess\n* Anatomical bronchial obstruction\n* Active or currently treated pulmonary tuberculosis\n* Atypical bacterial pneumonia, or viral pneumonia without bacterial superinfection, or need for antibiotic coverage with a macrolide\n* Pertussis, chemical pneumonitis, or cystic fibrosis\n* Severe immunodeficiency\n* Significant laboratory abnormalities including: Hematocrit \\<20%; absolute neutrophil count \\<0.5x10⁹/L; platelet count \\<50x10⁹/L; alanine aminotransferase, aspartate aminotransferase, or bilirubin \\>5 times the age-specific upper limit of normal;\n* Creatinine clearance \\<50 mL/min/1.73 m²\n* Use of systemic antimicrobial therapy for more than 24 hours in the 48 hours before randomization\n* History of a previous clinically-relevant hypersensitivity or serious adverse reaction to beta lactam antibiotics or to vancomycin\n* Poorly controlled seizure disorder\n* Other exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Months","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adverse Events","description":"Reported are adverse events (AEs) during the first 3 days of IV therapy and while patients were on IV therapy irrespective of when they switched to oral antibiotic treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Clinical Cure in the Intent-to-treat Population (ITT)","description":"Comparison of clinical cure rates (signs and symptoms of pneumonia normalized or improved such that no further antibiotic therapy was necessary, and stabilization or improvement of chest X-ray findings if these were available) in the ITT population between ceftobiprole and the comparator at the TOC visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Clinical Cure in the Clinically Evaluable (CE) Population","description":"Comparison of clinical cure rates (signs and symptoms of pneumonia normalized or improved such that no further antibiotic therapy was necessary, and stabilization or improvement of chest X-ray findings if these were available) in the CE population between ceftobiprole and the comparator at the TOC visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Early Clinical Response in the Intent-to-treat (ITT) Population","description":"Comparison of early clinical response rates in the ITT population between ceftobiprole and the comparator at Day 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Early Clinical Response in the Clinically Evaluable (CE) Population","description":"Comparison of early clinical response rates in the CE population between ceftobiprole and the comparator at Day 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":94},"commonTop":["Vomiting","Diarrhoea"]}}}